Genmab approval marks the era of bispecific antibodies in blood cancer treatment, says expert
In coming years, doctors will receive more ways to treat patients with hematologic cancers.
by ulrich quistgaard, translated by christian radich hoffman
The US Food and Drug Administration’s (FDA) approval of Epkinly (epcoritamab) from Genmab and Abbvie marks the beginning of a new chapter in the treatment of hematologic cancers. Bispecific antibodies have revolutionized the treatment of other cancer types and is now trying to do the same for the patients with blood cancers.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves cancer drug Epkinly from Genmab and Abbvie
For subscribers
